北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
作者: Zhao, Jialiang1; Li, Xiaoxin2; Tang, Shibo3; Xu, Gezhi4; Xu, Xun5; Zhang, Feng6; Zhang, Meixia7; Shamsazar, Jila8; Pilz, Stefan8; Nieweg, Annette8
刊名: BIODRUGS
发表日期: 2014-12-01
DOI: 10.1007/s40259-014-0106-1
卷: 28, 期:6, 页:527-536
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Immunology ; Pharmacology & Pharmacy
研究领域[WOS]: Oncology ; Immunology ; Pharmacology & Pharmacy
关键词[WOS]: VISUAL IMPAIRMENT ; CLINICAL-RESEARCH ; VERTEPORFIN ; EYE ; PREVALENCE ; THERAPY ; ANCHOR ; ACUITY
英文摘要:

Purpose To evaluate the efficacy and safety of monthly ranibizumab 0.5 mg in Chinese patients with subfoveal choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration (nAMD).

Methods A 12-month open-label single-arm multicenter phase III study that included treatment-na < ve (study eye) patients with primary/recurrent subfoveal CNV secondary to AMD. Patients (N = 114) aged >= 50 years with best-corrected visual acuity (BCVA) of 73-24 letters were treated with monthly ranibizumab for 12 months. Main outcomes were mean BCVA change from baseline to month 4 (primary endpoint) and over time to month 12, effects of ranibizumab treatment on retinal structure (months 4 and 12), and safety.

Results Ranibizumab led to significant improvements in mean BCVA +/- standard error (SE) at both months 4 and 12 versus baseline (+9.5 +/- 1.10 letters, 95 % confidence interval [CI] 7.3-11.7, and +12.7 +/- 1.14 letters, 95 % CI 10.4-14.9, respectively, both P < 0.0001). Ranibizumab prevented loss of vision (>= 0 letters BCVA gain) in 91.2 % of patients. Mean central retinal thickness +/- SE reduced from baseline to month 12 (-119.9 +/- 12.97 mu m, 95 % CI -145.59 to -94.20, P < 0.0001). No new safety findings were reported in this study.

Conclusion Ranibizumab administered monthly over 12 months was effective in improving BCVA and was well-tolerated in Chinese nAMD patients.

语种: 英语
项目资助者: Novartis Pharma AG, Switzerland
WOS记录号: WOS:000345993600005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52601
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Beijing Tongren Hosp, Beijing, Peoples R China
2.Novartis Pharma AG, Basel, Switzerland
3.Fudan Univ, Eyes & ENT Hosp, Shanghai 200433, Peoples R China
4.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100730, Peoples R China
5.Peking Univ, Peoples Hosp, Ctr Eye, Beijing 100871, Peoples R China
6.Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China
7.Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
8.Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China

Recommended Citation:
Zhao, Jialiang,Li, Xiaoxin,Tang, Shibo,et al. EXTEND II: An Open-Label Phase III Multicentre Study to Evaluate Efficacy and Safety of Ranibizumab in Chinese Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration[J]. BIODRUGS,2014,28(6):527-536.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhao, Jialiang]'s Articles
[Li, Xiaoxin]'s Articles
[Tang, Shibo]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhao, Jialiang]‘s Articles
[Li, Xiaoxin]‘s Articles
[Tang, Shibo]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace